Understand the clinical evidence for KAPRUVIA® (difelikefalin)
Overview
Learn with Dr Kieran McCafferty about the clinical trials evaluating the efficacy and safety of KAPRUVIA®, including the phase 3 KALM-1 and KALM-2 clinical trials with post-hoc pooled analysis and the KAPRUVIA® open-label safety study
This webinar is CPD accredited.
Download the certificate here once you have completed ALL chapters
Prescribing information and adverse event reporting information:
- Kapruvia®▼(difelikefalin): Click here
UK-DFK-2400102 (V3.0) | August 2025
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.
